A Prospective Open-Labeled Randomized Study of Rituximab Versus Standard of Care, for Treatment of Acute Allograft Rejection in Pediatric Renal Transplantation

Trial Profile

A Prospective Open-Labeled Randomized Study of Rituximab Versus Standard of Care, for Treatment of Acute Allograft Rejection in Pediatric Renal Transplantation

Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Jan 2016

At a glance

  • Drugs Antithymocyte globulin; Corticosteroids; Rituximab
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 11 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top